FDA to further investigate anemia drug risks

The FDA has announced that it plans to review data on key anemia drugs Aranesp, Epogen and Procrit which suggests that they can increase risks of death and tumor growth in women with breast or cervical cancers. These drugs, which are used to treat chemotherapy-induced anemia, have come under fire from two new studies which suggest that they can have serious impact on women's survival. For example, one study found that among 733 women getting chemotherapy before breast cancer surgery, 14 percent of those taking Aranesp had died after three years, as compared with 9.8 percent of those who didn't receive it. The drugs already bear a black box warning, but the FDA is considering unspecified "additional actions."

To find out more about the FDA's deliberations:
- read this Kaiser Daily Health Policy Report article

Related Articles:
New study points to danger of anemia drug. Report
Aetna limits anemia drug payments. Report
Dialysis firms defend anemia drug use along ethnic lines. Report
FDA group recommends anemia drug limits. Report
Anemia drug rebates challenged. Report
Regulators question anemia drugs. Report

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.